IGC 501
Alternative Names: IGC-501Latest Information Update: 23 Oct 2023
At a glance
- Originator India Globalization Capital
- Class Analgesics; Anti-inflammatories; Antiepileptic drugs; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Seizures
Most Recent Events
- 19 Oct 2023 IGC Pharma has patent protection for the patent titled 'Cannabinoid Composition and Method for Treating Pain' in the EU
- 17 Aug 2023 IGC Pharma receives notice of allowance from Commissioner of Patents, Canada for the use of cannabinoids in the treatment of seizures
- 17 Aug 2023 IGC Pharma's formulation receives an intent to grant from the European Patent Office for IGC 501